Abstract
We describe a case of intensively pruritic and partially bullous disseminated superficial actinic prorokeratosis, with acute flare-ups. Histopathological examination showed the characteristic cornoid lamella and subepidermal blister formation in one biopsy. Grenz ray treatment resulted in a marked regression of the skin lesions and pruritus.
References
1.
Stephen P, Shumac MB, Commens AC: Disseminated superficial porokeratosis: A clinical study. J Am Acad Dermatol 1989;20:1015– 1022.
2.
Shimamoto H: Differentiation of disseminated superficial actinic porokeratosis from superficial disseminated eruptive form of porokeratosis of Mibelli. Cutis 1988;42:345–348.
3.
Helfman RJ, Poulos EG: Reticulated porokeratosis. Arch Dermatol 1985;121:1542–1543.
4.
Bencini PL, Tarantino A, Grimalt R, Ponticelli C, Caputo R: Porokeratosis and immunosuppression. Br J Dermatol 1995;132:74–78.
5.
Herranz P, Pizarro A, De Luca R, Robayna MG, Rubio FA, Sanz A, Contreras F, Casado M: High incidence of porokeratosis in renal transplant recipients. Br J Dermatol 1997;136:176– 179.
6.
Rothman IL, Wirth PB, Klaus MV: Porokeratosis of Mibelli following heart transplant. Int J Dermatol 1992;31:52–54.
7.
Fields LL, White CR, Maziarz RT: Rapid development of disseminated superficial porokeratosis after transplant induction therapy. Bone Marrow Transplant 1995;15:993–995.
8.
Zenarola P, Melillo L, Lomuto M, Carotenuto M, Gomes VE, Marzocchi W: Exacerbation of porokeratosis: A sign of immunodepression. J Am Acad Dermatol 1993;29:1035–1036.
9.
Luelmo-Aguilar J, Gonzalez-Castro U, Mieras-Barcelo C, Castells-Rodellas A: Disseminated porokeratosis and myelodysplastic syndrome. Dermatology 1992;184:289.
10.
Neumann RA, Knobler RM, Metze D, Jurecka W: Disseminated superficial porokeratosis and immunosuppression. Br J Dermatol 1988;119: 375–380.
11.
Kanitakis J, Misery L, Nicolas JF, Lyonnet S, Chouvet B, Haftek M, Faure M, Claudy A, Thivolet J: Disseminated superficial porokeratosis in a patient with AIDS. Br J Dermatol 1994;131:284–289.
12.
Chernosky ME, Freeman RG: Disseminated superficial actinic porokeratosis. Arch Dermatol 1967;96:611–624.
13.
Kanzaki T, Miwa N, Kobayashi T, Ogawa S: Eruptive pruritic papular porokeratosis. J Dermatol 1992;19:109–112.
14.
Harrison PV, Stollery N: Disseminated superficial actinic porokeratosis responding to calcipotriol. Clin Exp Dermatol 1994;19:95.
15.
Danno K, Yamamoto M, Yokoo T, Ohta M: Etretinate treatment in disseminated porokeratosis. J Dermatol 1988;15:440–444.
16.
Shelley WB, Shelley ED: Disseminated superficial porokeratosis: Rapid therapeutic response to 5-fluorouracil. Cutis 1983;32:139–140.
17.
Schwarz T, Seiser A, Gschnait F: Disseminated superficial actinic porokeratosis. J Am Acad Dermatol 1984;19:95.
18.
Chernowsky ME, Anderson DE: Disseminated superficial actinic porokeratosis: Clinical studies and experimental production of the lesions. Arch Dermatol 1969;99:401–407.
19.
Shumack S, Commens C, Kossard S: Disseminated superficial actinic porokeratosis: A histological review of 61 cases with particular references to lymphocytic inflammation. Am J Dermatopathol 1991;13:26–31.
20.
Reed RJ, Leone P: Porokeratosis: A mutant clonal keratosis of the epidermis. Arch Dermatol 1979;101:340–347.
21.
Watanabe R, Otsuka F: Cultured skin fibroblasts from three patients with disseminated superficial actinic porokeratosis are hypersensitive to the letal effects of X-radiation but not to those of ultraviolet (UV) light. Exp Dermatol 1993;2:175–178.
22.
Neuman RA, Knobler RM, Jerucka W, Gebhart W: Disseminated superficial actinic porokeratosis: Experimental induction and exacerbation of skin lesions. J Am Acad Dermatol 1989;21: 1182–1189.
23.
Romani J, Pujol RM, Casanova JM, De Moragas JM: Disseminated superficial porokeratosis developing after electron-beam total skin irradiation for mycosis fungoides. Clin Exp Dermatol 1996;21:310–312.
24.
Shrum JR, Cooper PH, Greer KE, Landes HB: Squamous cell carcinoma in disseminated superficial actinic porokeratosis. J Am Acad Dermatol 1982;6:58–62.
25.
Otsuka F, Someya T, Ishibashi Y: Porokeratosis and malignant skin tumours. J Cancer Res Clin Oncol 1991;117:55–60.
26.
Watanabe R, Ishibashi Y, Otsuka F: Chromosomal instability and cellular hypersensitivity to X-radiation of cultured fibroblasts derived from porokeratosis patients’ skin. Mutat Res 1990; 230:273–278.
27.
Otsuka F, Watanabe R, Moro A, Ohhkochi H, Ishibashi Y: Cultured skin fibroblasts from patients with porokeratosis are hypersensitive to the letal effects of X-radiation. Jpn J Cancer Res 1989;80:41–44.
28.
Frenz G: Grenz ray-induced nonmelanoma skin cancer. J Am Acad Dermatol 1989;21:475– 478.
29.
Rowell N: Adverse effects of superficial X-ray therapy and recommendations for safe use in benign dermatoses. J Dermatol Surg Oncol 1978;4:630–634.
30.
Kalz F: Observations on grenz ray reactions. Dermatologica 1959;118:357–371.
31.
Mortensen AC, Kjeldsen H: Carcinomas following grenz ray treatment of benign dermatoses. Acta Dermatol Venereol 1987;67: 523–525.
32.
Lindelöf B: Grenz-ray therapy; in Goldschmidt H, Panizzon RG (eds): Modern Dermatologic Radiation Therapy. New York, Springer, 1991, pp 155–159.
33.
Lindelöf B, Eklund G: Incidence of malignant skin tumors in 14,140 patients after grenz-ray treatment for benign dermatoses. Arch Dermatol 1986;122:1391–1395.
© 2000 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
